<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098522</article-id><article-id pub-id-type="publisher-id">1467504</article-id><article-id pub-id-type="doi">10.3389/fphar.2025.1467504</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Target screening and optimization of candidate compounds for breast cancer treatment using bioinformatics and computational chemistry approaches</article-title><alt-title alt-title-type="left-running-head">Xu et al.</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xlink:href="https://doi.org/10.3389/fphar.2025.1467504" ext-link-type="uri">10.3389/fphar.2025.1467504</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Jian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2833548/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Xue</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><xref rid="fn1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><uri xlink:href="https://loop.frontiersin.org/people/3043209/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jia</surname><given-names>Yiduo</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/2796803/overview"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Shaoxing People&#x02019;s Hospital</institution>, <addr-line>Shaoxing</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>School of Medicine and Pharmacy, Wuhan University of Bioengineering</institution>, <addr-line>Wuhan</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>School of Chemical Engineering and Pharmacy</institution>, <institution>Wuhan Institute of Technology</institution>, <addr-line>Wuhan</addr-line>, <country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation</institution>, <institution>School of Pharmacy</institution>, <institution>Huazhong University of Science and Technology</institution>, <addr-line>Wuhan</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/2695599/overview" ext-link-type="uri">H&#x000e9;lcio Silva Dos Santos</ext-link>, Universidade Estadual do Vale do Acara&#x000fa;, Brazil</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/905002/overview" ext-link-type="uri">Jun Shang</ext-link>, Cincom System, Inc., United States</p><p>
<ext-link xlink:href="https://loop.frontiersin.org/people/1794551/overview" ext-link-type="uri">Dipendra Khadka</ext-link>, NADIANBIO Co. Ltd., Wonkwang University School of Medicine, South Korea</p></fn><corresp id="c001">*Correspondence: Xue Li, <email>lee0020060@whsw.edu.cn</email>; Yiduo Jia, <email>jiayiduo0402@163.com</email>
</corresp><fn fn-type="equal" id="fn1"><label>
<sup>&#x02020;</sup>
</label><p>These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1467504</elocation-id><history><date date-type="received"><day>20</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Xu, Li and Jia.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Xu, Li and Jia</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Objectives</title><p>This study aimed to identify critical therapeutic targets and design potent antitumor compounds for breast cancer treatment through an integrated bioinformatics and computational chemistry approach.</p></sec><sec><title>Methods</title><p>We conducted initial screening and target intersection analysis to identify potential protein targets, highlighting the adenosine A1 receptor as a key candidate. Molecular docking and molecular dynamics (MD) simulations were performed to evaluate the binding stability between selected compounds and the human adenosine A1 receptor-Gi2 protein complex (PDB ID: 7LD3). A pharmacophore model was constructed based on binding information to guide the virtual screening of additional compounds with activity. Furthermore, we designed and synthesized a novel molecule based on this model, followed by <italic>in vitro</italic> biological evaluation using MCF-7 breast cancer cells.</p></sec><sec><title>Results</title><p>Compound 5 exhibited stable binding to the adenosine A1 receptor, as confirmed by docking and MD simulations. Pharmacophore-based screening identified compounds 6&#x02013;9 with strong binding affinities. These findings guided Molecule 10, which was rationally designed and synthesized, showing potent antitumor activity against MCF-7 cells with an IC50 value of 0.032 &#x000b5;M, significantly outperforming the positive control 5-FU (IC50 = 0.45&#x000a0;&#x000b5;M).</p></sec><sec><title>Conclusion</title><p>This study advances the understanding of molecular interactions in breast cancer therapy and demonstrates the potential of Molecule 10 as a highly effective therapeutic candidate. Integrating reverse drug screening, molecular modelling, and <italic>in vitro</italic> validation provides a robust platform for future drug discovery in breast cancer treatment.</p></sec></abstract><kwd-group><kwd>cancer</kwd><kwd>dock</kwd><kwd>targeted therapy</kwd><kwd>computational analysis</kwd><kwd>breast</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Experimental Pharmacology and Drug Discovery</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>Breast cancer, a malignant tumour originating in breast tissue, remains one of the most prevalent cancers worldwide, primarily affecting women but also occurring in men at lower frequencies. Its incidence and mortality rates vary significantly across regions due to genetic, environmental, hormonal, and lifestyle factors (<xref rid="B30" ref-type="bibr">Neagu et al., 2023</xref>). Extensive research has sought to unravel the complexities of breast cancer biology, focusing on its aetiology, risk factors, and molecular mechanisms underlying its initiation, progression, and metastasis. These studies have laid the foundation for developing personalized and targeted therapeutic strategies (<xref rid="B16" ref-type="bibr">Herdiana et al., 2023</xref>).</p><fig position="float" id="sch1"><label>SCHEME 1</label><caption><p>Regends and conditions.</p></caption><graphic xlink:href="FPHAR_fphar-2025-1467504_wc_sch1" position="float"/></fig><p>Cell models are critical in advancing breast cancer research (<xref rid="B46" ref-type="bibr">Zhang et al., 2024</xref>). Among these, the estrogen receptor-positive (ER+) MCF-7 cell line, derived from human breast cancer tissue, is widely used to investigate the estrogen dependency of breast cancer and to evaluate therapies targeting estrogen signalling pathways. In contrast, the MDA-MB cell line, characterized by its lack of estrogen receptor expression (ER-), is primarily employed for studying more aggressive breast cancer behaviours, such as metastasis and drug resistance. Together, these cell models provide valuable insights into the heterogeneity of breast cancer and facilitate the development of novel treatment strategies (<xref rid="B34" ref-type="bibr">&#x000d6;zgen et al., 2025</xref>).</p><p>Target-based drug discovery has emerged as a promising approach for accelerating drug development in cancer research (<xref rid="B39" ref-type="bibr">Tauro et al., 2025</xref>). By leveraging bioinformatics and computational chemistry, researchers can efficiently identify key molecular targets and screen potential compounds with high binding affinities. For instance, Sunitinib (<xref rid="B2" ref-type="bibr">Azimian and Dastmalchi, 2023</xref>), an angiogenesis inhibitor used in the treatment of renal cell carcinoma and gastrointestinal stromal tumours, was developed through the application of computational chemistry methods to optimize its molecular structure, enhancing its selectivity and activity against specific tyrosine kinase targets. Similarly, Pazopanib, employed for treating renal cell carcinoma and soft tissue sarcoma, was identified using computational techniques focused on its interactions with multiple receptor tyrosine kinases, ultimately leading to its clinical approval (<xref rid="B28" ref-type="bibr">Menezes et al., 2021</xref>). This strategy enhances our understanding of molecular interactions in cancer and supports the rational design of structure-based therapies (<xref rid="B12" ref-type="bibr">Gahbauer et al., 2023</xref>).</p><p>This study employs a bioinformatics and computational chemistry approach to identify novel therapeutic targets and compounds for breast cancer treatment, providing a scientifically rational framework for drug discovery. By integrating computational tools such as molecular docking, molecular dynamics simulations, and pharmacophore modelling, we aim to enhance the precision and efficiency of identifying compounds that specifically interact with key proteins involved in breast cancer progression. This method contributes to a deeper understanding of the molecular interactions in breast cancer therapy and aligns with the growing need for personalized and targeted treatment strategies. Our approach offers a promising pathway for discovering potential lead compounds, ultimately advancing the development of more effective and tailored therapies for breast cancer patients.</p></sec><sec sec-type="materials|methods" id="s2"><title>2 Materials and methods</title><p>The experimental procedure was performed with an Intel Xeon CPU E5-2650, 2.00&#x000a0;GHz processor, using a Windows 10 operating system and a 4&#x000a0;GB NVIDIA Quadro 2000 graphics card. VMD 1.9.3 was used as a 3D visualization window.</p><p>This study systematically analyzed 23 compounds selected from 23 publications (<xref rid="B1" ref-type="bibr">Adams et al., 2002</xref>; <xref rid="B5" ref-type="bibr">Benedekovic et al., 2020</xref>; <xref rid="B4" ref-type="bibr">Benedekovi&#x00107; et al., 2020</xref>; <xref rid="B6" ref-type="bibr">Bheeram et al., 2019</xref>; <xref rid="B7" ref-type="bibr">Bohyun et al., 2016</xref>; <xref rid="B8" ref-type="bibr">Devendar et al., 2014</xref>; <xref rid="B11" ref-type="bibr">Dulong et al., 2013</xref>; <xref rid="B13" ref-type="bibr">Gerhard et al., 2010</xref>; <xref rid="B15" ref-type="bibr">Haiwen et al., 2007</xref>; <xref rid="B17" ref-type="bibr">Holger et al., 2012</xref>; <xref rid="B19" ref-type="bibr">Huzaifa et al., 2018</xref>; <xref rid="B20" ref-type="bibr">Ihmaid et al., 2022</xref>; <xref rid="B21" ref-type="bibr">Jojart et al., 2021</xref>; <xref rid="B22" ref-type="bibr">Khan et al., 2022</xref>; <xref rid="B26" ref-type="bibr">Maria et al., 2012</xref>; <xref rid="B29" ref-type="bibr">Nakhjiri et al., 2012</xref>; <xref rid="B32" ref-type="bibr">Nejat et al., 2018b</xref>; <xref rid="B33" ref-type="bibr">Noor et al., 2021</xref>; <xref rid="B35" ref-type="bibr">Rebeka et al., 2020</xref>; <xref rid="B36" ref-type="bibr">Satish Kumar et al., 2019</xref>; <xref rid="B38" ref-type="bibr">Tamizharasan et al., 2020</xref>; <xref rid="B40" ref-type="bibr">Thomas et al., 2005</xref>; <xref rid="B43" ref-type="bibr">Wukun et al., 2012</xref>; <xref rid="B44" ref-type="bibr">Wukun et al., 2011</xref>), each demonstrating significant inhibitory effects on MDA-MB and MCF-7 breast cancer cell lines. Initially, three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses were performed to evaluate the spatial diversity of these compounds. Through conformational optimization, a total of 249 distinct conformers were generated. Subsequently, a split analysis, as depicted in <xref rid="F1" ref-type="fig">Figure 1</xref>, was conducted to construct five pharmacophore models. These models, defined based on spatial differences, were screening tools to identify key structural features influencing biological activity. Each of the five pharmacophores exhibited significant spatial diversity. From these, the most potent compound within each pharmacophore category was selected, and detailed information about these compounds is presented in <xref rid="T1" ref-type="table">Table 1</xref>.</p><fig position="float" id="F1"><label>FIGURE 1</label><caption><p>Split analysis of 249 compounds.</p></caption><graphic xlink:href="fphar-16-1467504-g001" position="float"/></fig><table-wrap position="float" id="T1"><label>TABLE 1</label><caption><p>Compounds of anti-MCF-7 and MDA-MB tumour cells.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th rowspan="2" align="center" colspan="1">Compounds</th><th rowspan="2" align="center" colspan="1">Structural formula</th><th colspan="2" align="center" rowspan="1">IC50 (&#x000b5;M)</th></tr><tr><th align="center" rowspan="1" colspan="1">MCF-7</th><th align="center" rowspan="1" colspan="1">MDA-MB</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">1 (<xref rid="B22" ref-type="bibr">Khan et al., 2022</xref>)</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2025-1467504_wc_tfx1.jpg"/>
</td><td align="center" rowspan="1" colspan="1">3.4</td><td align="center" rowspan="1" colspan="1">4.7</td></tr><tr><td align="center" rowspan="1" colspan="1">2 (<xref rid="B4" ref-type="bibr">Benedekovi&#x00107; et al., 2020</xref>)</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2025-1467504_wc_tfx2.jpg"/>
</td><td align="center" rowspan="1" colspan="1">0.21</td><td align="center" rowspan="1" colspan="1">0.16</td></tr><tr><td align="center" rowspan="1" colspan="1">3 (<xref rid="B31" ref-type="bibr">Nejat et al., 2018a</xref>)</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2025-1467504_wc_tfx3.jpg"/>
</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2.5</td></tr><tr><td align="center" rowspan="1" colspan="1">4 (<xref rid="B38" ref-type="bibr">Tamizharasan et al., 2020</xref>)</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2025-1467504_wc_tfx4.jpg"/>
</td><td align="center" rowspan="1" colspan="1">0.57</td><td align="center" rowspan="1" colspan="1">0.42</td></tr><tr><td align="center" rowspan="1" colspan="1">5 (<xref rid="B20" ref-type="bibr">Ihmaid et al., 2022</xref>)</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2025-1467504_wc_tfx5.jpg"/>
</td><td align="center" rowspan="1" colspan="1">3.47</td><td align="center" rowspan="1" colspan="1">1.43</td></tr></tbody></table></table-wrap><p>The compounds listed in <xref rid="T1" ref-type="table">Table 1</xref> exhibit significant structural diversity, which may lead to interactions with multiple targets within biological systems, thereby increasing the complexity of drug action and providing a broader range of potential targets. The SwissTargetPrediction Database (<ext-link xlink:href="http://swisstargetprediction.ch" ext-link-type="uri">http://swisstargetprediction.ch</ext-link>) was employed to predict these potential interactions. Using the chemical structures of the selected compounds as input and specifying &#x0201c;<italic>Homo sapiens</italic>&#x0201d; as the species, potential therapeutic targets were identified, offering valuable insights for further research.</p><sec id="s2-1"><title>2.1 Virtual screening</title><sec id="s2-1-1"><title>2.1.1 Intersection of compounds against breast cancer</title><p>Five anticancer drugs, designed with distinct philosophies, share common antitumor targets against MDA-MB and MCF-7 breast cancer cell lines. The references for these five drugs, as introduced in <xref rid="T1" ref-type="table">Table 1</xref>, provide detailed descriptions of their spatial configurations. Utilizing the online tool &#x0201c;<ext-link xlink:href="https://bioinfogp.cnb.csic.es/tools/venny/index.html" ext-link-type="uri">https://bioinfogp.cnb.csic.es/tools/venny/index.html</ext-link>,&#x0201d; we conducted an intersection analysis of the 500 predicted targets of these five compounds, revealing a shared target (<xref rid="B37" ref-type="bibr">Sihombing et al., 2024</xref>).</p></sec><sec id="s2-1-2"><title>2.1.2 Screening of compounds against breast cancer through the PubChem database</title><p>To further screen the targets and study the interactions between the targets, we screened the targets of two proteins through the PubChem Database (<ext-link xlink:href="https://pubchem.ncbi.nlm.nih.gov/" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/</ext-link>) (<xref rid="B25" ref-type="bibr">Lv et al., 2023</xref>), and the source used was the keywords &#x0201c;MDA-MB and MCF-7&#x0201d; were used to screen out the protein targets of the drug.</p></sec><sec id="s2-1-3"><title>2.1.3 Molecular docking simulation and validation</title><p>In this process, we created a ligand library using Discovery Studio 2019 Client, performed docking with CHARMM to refine ligand shapes and charge distribution, and analyzed binding interactions between compounds and drug targets. <xref rid="T4" ref-type="table">Table 4</xref> contains the LibDockScore results, representing the best-scoring outcomes based on the binding sites reported in the existing literature. We selected the best poses based on LibDock scores, filtering targets with scores over 130, providing valuable insights into the binding mechanisms for our research (<xref rid="B14" ref-type="bibr">Guo et al., 2024</xref>).</p></sec><sec id="s2-1-4"><title>2.1.4 The stability of the docked complexes studied by molecular dynamics (MD) simulation</title><p>Molecular dynamics (MD) simulations using GROMACS 2020.3 analyzed protein-ligand binding dynamics. Protein structures were optimized with the AMBER99SB-ILDN force field (<xref rid="B41" ref-type="bibr">Vieira et al., 2023</xref>), and water molecules were modelled with the TIP3P model (<xref rid="B9" ref-type="bibr">Dorrani and Mohebbi, 2023</xref>). ACPYPE calculated ligand charges and generated GAFF force field-compatible files (<xref rid="B45" ref-type="bibr">Zaremba et al., 2023</xref>). Simulations employed cubic boxes with a minimum atom-box boundary distance of 0.8 nm, hydrated with SOL water at 1000&#x000a0;g/L density. Chloride ions replaced solvent water for electrical neutrality. An initial energy minimization step relaxed the system, followed by a 150 ps restrained Molecular dynamics (MD) simulation at 298.15&#x000a0;K. Unrestricted Molecular dynamics (MD) simulations with a time step of 0.002 ps were performed for 15 ns, maintaining isothermal-isobaric conditions at 298.15 K and 1&#x000a0;bar pressure, controlled by thermostats and barostats.</p></sec><sec id="s2-1-5"><title>2.1.5 The distribution of dynamic binding positions of compound 5</title><p>We extensively summarized the motion trajectory of the molecule interacting with the target using VMD 1.9.3 software. This comprehensive analysis spans from the initial to the 8220th frame, with data recorded every 200 frames. This frequency of data capture allowed for meticulous observation and documentation of the molecule&#x02019;s dynamics throughout this timeframe, facilitating a thorough understanding of the molecular binding process to the target (<xref rid="B18" ref-type="bibr">Hsieh et al., 2023</xref>). Employing this systematic analytical approach aids in elucidating the molecule&#x02019;s dynamic behaviour during the binding process, potential intermediate states, and the temporal sequence of binding events.</p></sec><sec id="s2-1-6"><title>2.1.6 Binding force analysis</title><p>We utilized Discovery Studio 2019 Client to analyze the interaction between molecules and proteins (<xref rid="B3" ref-type="bibr">Baroroh et al., 2023</xref>). From a quantum chemical perspective, the interaction between molecules and proteins involves three primary binding forces: hydrogen bonds, electrostatic forces, and hydrophobic forces. Hydrogen bonds, characterized by interactions between hydrogen atoms and electronegative atoms such as oxygen or nitrogen, play a crucial role in stabilizing the interaction between molecules and proteins. Electrostatic forces, arising from the attraction or repulsion between charged particles, facilitate the interaction between oppositely charged regions of proteins and molecules, enhancing their binding affinity. Additionally, hydrophobic forces, stemming from the tendency of nonpolar molecules to avoid water, drive the clustering of hydrophobic residues within proteins, thereby promoting interactions with hydrophobic regions of molecules and strengthening the overall binding stability. Collectively, these binding forces dictate the mode, strength, and functional implications of molecular-protein interactions, offering critical insights into protein structure-function relationships and guiding drug design strategies in scientific research.</p></sec><sec id="s2-1-7"><title>2.1.7 Protein subcellular localization</title><p>Subcellular localization refers to the precise cellular location of a protein or its gene expression product, encompassing compartments such as the nucleus, cytoplasm, and cell membrane. This spatial organization is crucial for the protein&#x02019;s proper function, as it ensures access to the necessary chemical environment and interacting factors. Misplacement can disrupt cellular processes, making understanding protein localization essential for studying gene functions, protein interactions, and their mechanisms[20].</p><p>PSORT is a computer program used to predict the subcellular location of proteins based on their amino acid sequences and source information. To predict subcellular localization, the amino acid sequences of target proteins are obtained from the UniProt Database, and these sequences are then input into the PSORT II online software (<ext-link xlink:href="https://psort.hgc.jp/" ext-link-type="uri">https://psort.hgc.jp/</ext-link>). PSORT II provides predictions regarding the subcellular location of the target proteins (<xref rid="B23" ref-type="bibr">Li et al., 2023</xref>).</p></sec><sec id="s2-1-8"><title>2.1.8 Docking study</title><p>We have identified the interaction sites of drugs and their targets through subcellular localization, confirming where the compounds exert their effects on the human adenosine A1 receptor-Gi2 protein target. By reviewing relevant literature on this target, we found diverse structural designs for drugs targeting the A1 receptor. Despite significant differences in their molecular structures, these compounds exhibit strong interactions with the target. Therefore, we conducted a molecular docking study to evaluate the interactions between the target and these compounds. This approach allowed us to assess the binding affinities and interaction mechanisms, providing insights into the design principles for developing effective human adenosine A1 receptor-Gi2 protein inhibitors.</p></sec><sec id="s2-1-9"><title>2.1.9 Pharmacophores construction</title><p>The compounds exhibit significant differences in spatial structures, yet they all demonstrate strong interactions with the target. Based on their spatial structures and interactions with the target, we constructed a pharmacophore model using Discovery Studio 2019. The pharmacophore model was then used to screen our designed compound library (<xref rid="B47" ref-type="bibr">Jia et al., 2023</xref>).</p><p>The pharmacophore model represents the essential features responsible for the biological activity of the compounds. These features include hydrogen bond acceptors and donors, hydrophobic regions, and aromatic rings critical for the binding to the target. By leveraging this model, we were able to identify potential compounds from our library that fit the pharmacophore and are likely to interact effectively with the target. This approach not only streamlined the identification of promising compounds but also provided a rational basis for designing and optimizing new inhibitors targeting the human adenosine A1 receptor-Gi2 protein.</p></sec></sec><sec id="s2-2"><title>2.2 Chemistry</title><sec id="s2-2-1"><title>2.2.1 Synthesis route of molecule 10</title><p>All reagents and starting materials were obtained from commercial suppliers and used without further purification. The progress of the reactions was monitored using analytical thin-layer chromatography (TLC) on GF254 precoated plates, visualized with a UV lamp and iodine (I2) staining. Column chromatography used Acme silica gel (200&#x02013;300 mesh) with dichloromethane, methanol, petroleum ether, and ethyl acetate as eluents. <sup>1</sup>H NMR spectra were recorded at 300 and 500&#x000a0;MHz, and <sup>13</sup>C NMR spectra at 75 and 125&#x000a0;MHz, using a Bruker Avance spectrometer. Deuterated chloroform (CDCl3), dimethyl sulfoxide-d6 (DMSO-<italic>d</italic>
<sub>6</sub>), or deuterium oxide (D2O) were used as solvents, with tetramethylsilane (TMS) as the internal standard. Chemical shifts are reported in parts per million (&#x003b4;) downfield from TMS. NMR signal abbreviations include s = singlet, br s = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and dd = doublet of doublets. Melting points were measured using a Micro melting point apparatus SGWX-4 without correction. LCMS spectra were recorded using a QSTAR XL hybrid MS/MS system with methanol as the solvent. High-performance liquid chromatography (HPLC) was conducted using UltiMate 3000 equipment comprising a Variable Wavelength Detector, Autosampler, and pump to determine product purity. The column used was an Acclaim<sup>&#x000ae;</sup> 120 C18 (5&#x000a0;&#x003bc;m, 120&#x000a0;&#x000c5;, 4.6 &#x000d7; 250&#x000a0;mm). The flow rate was set to 1.00&#x000a0;mL/min, with an injection volume of 5.0&#x000a0;&#x000b5;L and detection at 254&#x000a0;nm for 30&#x000a0;min. The solvents were: A: water; B: acetonitrile; C: water with 0.5% (vol/vol) trifluoroacetic acid. An isocratic elution with 85% B was performed from 0 to 7&#x000a0;min. Detailed synthetic procedures and spectroscopic data are provided in the Supporting Information.</p></sec></sec><sec id="s2-3"><title>2.3 Activity</title><sec id="s2-3-1"><title>2.3.1 <italic>In vitro</italic> activity assay</title><p>Due to the restricted availability of MDA-MB cell lines, we cannot evaluate the anti-breast cancer activity using MCF-7 cell lines. To inhibit MCF-7 cell lines, we chose the MTT ratio, cell calculation, and selective adsorption of the synthesized drugs.</p><p>Human liver tumour MCF-7 cell lines (kindly presented by Prof. Xiang Ming, Tongji Medical College, Huazhong University of Science and Technology); DMEM high sugar medium (Hyclone); penicillin, streptomycin (Hyclone, production lot no. 16677148); 0.25% trypsin, dimethyl sulfoxide (DMSO). Pentafluorouracil (5-FU) (analytical purity, Sigma, USA); fetal bovine serum (Zhejiang Tian hang Biotechnology Co., Ltd.); phosphate buffer solution (PBS) (Shanghai Double Helix Biotechnology Co., Ltd.); compounds 10.</p></sec></sec></sec><sec sec-type="results" id="s3"><title>3 Results</title><sec id="s3-1"><title>3.1 Virtual screening</title><sec id="s3-1-1"><title>3.1.1 Screening of anti-breast cancer protein targets of five compounds</title><p>We screened 500 targets using the SwissTargetPrediction Database, and <xref rid="F2" ref-type="fig">Figure 2</xref> displays the targets for five compounds. The Family A&#x000a0;G protein-coupled receptor ranks among the top three.</p><fig position="float" id="F2"><label>FIGURE 2</label><caption><p>Target classes of five Compounds.</p></caption><graphic xlink:href="fphar-16-1467504-g002" position="float"/></fig></sec><sec id="s3-1-2"><title>3.1.2 Intersection of anti-breast cancer protein targets of five compounds</title><p>Through Venny 2.1.0 (csic.es)(<ext-link xlink:href="https://bioinfogp.cnb.csic.es/tools/venny/index.html" ext-link-type="uri">https://bioinfogp.cnb.csic.es/tools/venny/index.html</ext-link>) online software, we screened two targets from 500 targets of three compounds, as shown in <xref rid="F3" ref-type="fig">Figure 3</xref>. The targets are shown in <xref rid="T2" ref-type="table">Table 2</xref>.</p><fig position="float" id="F3"><label>FIGURE 3</label><caption><p>Venn diagram of targets from five compounds. 1. Note: &#x0201c;1, 2, and 3&#x0201d; represent the intersecting targets of Compound 1, Compound 2, and Compound 3 shown in the left diagram.</p></caption><graphic xlink:href="fphar-16-1467504-g003" position="float"/></fig><table-wrap position="float" id="T2"><label>TABLE 2</label><caption><p>The screened targets by Venn.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Public protein</th><th align="center" rowspan="1" colspan="1">Target</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">Adenosine receptor A2a</td><td align="center" rowspan="1" colspan="1">ADORA2A</td></tr><tr><td align="center" rowspan="1" colspan="1">Adenosine receptor A1</td><td align="center" rowspan="1" colspan="1">THE ADENOSINE A1 RECEPTOR</td></tr></tbody></table></table-wrap></sec><sec id="s3-1-3"><title>3.1.3 Screening of anti-breast cancer protein targets of five compounds through PubChem database</title><p>After screening proteins via PubChem (<ext-link xlink:href="http://nih.gov" ext-link-type="uri">nih.gov</ext-link>) (<ext-link xlink:href="https://puchem.ncbi.nlm.nih.gov/" ext-link-type="uri">https://puchem.ncbi.nlm.nih.gov/</ext-link>) in <xref rid="T3" ref-type="table">Table 3</xref>, we discovered the significant importance of THE ADENOSINE A1 RECEPTOR protein in anti-breast cancer therapy. THE ADENOSINE A1 RECEPTOR protein, a type of adenosine receptor, plays a crucial role in regulating biological processes such as cell proliferation, apoptosis, and migration. Studies have indicated a close correlation between the expression levels of THE ADENOSINE A1 RECEPTOR protein in breast cancer cells and tumour growth, metastasis, and treatment sensitivity. Its regulatory role in cellular signalling pathways makes it a potential target for anti-breast cancer therapy. Therefore, further research into THE ADENOSINE A1 RECEPTOR protein and exploring compounds' interaction may provide new therapeutic strategies and drug design directions for breast cancer treatment. Conversely, ADORA2A protein shows lower relevance to breast cancer proteins. Consequently, subsequent studies will focus on the screening and analysis of THE ADENOSINE A1 RECEPTOR protein, aiming to delve deeper into its potential role and clinical applications in breast cancer treatment.</p><table-wrap position="float" id="T3"><label>TABLE 3</label><caption><p>Results of screened targets by PubChem Database.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Target</th><th align="center" rowspan="1" colspan="1">PDB ID</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">Adenosine A1 receptor</td><td align="center" rowspan="1" colspan="1">5N2S,6D9H,7LD3</td></tr><tr><td align="center" rowspan="1" colspan="1">ADORA2A</td><td align="center" rowspan="1" colspan="1">6ZDR, 7PX4, 8C9W, 8FYN, 8GNE, 8RQQ, 6LPJ, 6WQA, 8CU7, 8JWY, 8PWN</td></tr></tbody></table></table-wrap></sec><sec id="s3-1-4"><title>3.1.4 Molecular docking simulation and validation</title><p>The adenosine A1 receptor plays multiple roles in the tumour microenvironment, particularly in breast cancer and other tumours. THE ADENOSINE A1 RECEPTOR is closely associated with antitumor immunity, apoptosis, and the inhibition of tumour proliferation. Upon activation, THE ADENOSINE A1 RECEPTOR mediates its effects via G protein-coupled signaling pathways, inhibiting cancer cell proliferation and promoting apoptosis. In breast cancer cell lines such as MDA-MB and MCF-7, the role of THE ADENOSINE A1 RECEPTOR extends beyond direct effects on tumour cells to modulate the immune system. Specifically, ADENOSINE A1 RECEPTOR activation promotes T cell-mediated antitumor immunity, enhancing the body&#x02019;s immune response against cancer cells.</p><p>In contrast, ADORA2A (Adenosine A2A receptor) primarily contributes to immune suppression in the tumour microenvironment. ADORA2A regulates immune cells, such as T and dendritic cells, to facilitate tumour immune evasion. This suppression of the immune response enables the tumour to escape immune detection and grow. Therefore, in breast cancer research, THE ADENOSINE A1 RECEPTOR is prioritized over ADORA2A due to its pivotal role in regulating immune responses, inhibiting tumour growth, and promoting apoptosis. While ADORA2A&#x02019;s role in immune evasion and suppression is important, THE ADENOSINE A1 RECEPTOR holds more potential for directly combating tumour progression, making it an ideal target for cancer therapy.</p><p>We also conducted molecular docking studies using Discovery Studio 2019 Client to investigate the interactions between five compounds and three target proteins. In this study, we used LibDockScore to quantify the binding affinity between molecules. Compounds with a LibDockScore exceeding 130 during the docking process were considered significant binders, as shown in <xref rid="T4" ref-type="table">Table 4</xref>. This threshold was selected to prioritize compounds with higher binding affinity, thus identifying them as strong candidates for further investigation. Notably, none of the five compounds showed significant interactions with ADORA2A-related targets. Therefore, based on the current molecular docking results, the anticancer activity of these compounds appears to be unrelated to ADORA2A.</p><table-wrap position="float" id="T4"><label>TABLE 4</label><caption><p>Results of docking.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Target</th><th align="center" rowspan="1" colspan="1">Compound</th><th align="center" rowspan="1" colspan="1">libdockscore</th><th align="center" rowspan="1" colspan="1">Absolute energy</th><th align="center" rowspan="1" colspan="1">Relative energy</th></tr></thead><tbody valign="top"><tr><td rowspan="5" align="center" colspan="1">5N2S</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">110.463</td><td align="center" rowspan="1" colspan="1">60.3866</td><td align="center" rowspan="1" colspan="1">4.91131</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">126.078</td><td align="center" rowspan="1" colspan="1">57.4398</td><td align="center" rowspan="1" colspan="1">19.6871</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">116.618</td><td align="center" rowspan="1" colspan="1">57.4614</td><td align="center" rowspan="1" colspan="1">5.61654</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">111.041</td><td align="center" rowspan="1" colspan="1">77.7491</td><td align="center" rowspan="1" colspan="1">0.0629889</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">133.462</td><td align="center" rowspan="1" colspan="1">57.6704</td><td align="center" rowspan="1" colspan="1">7.47434</td></tr><tr><td rowspan="5" align="center" colspan="1">6D9H</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">80.3367</td><td align="center" rowspan="1" colspan="1">56.4111</td><td align="center" rowspan="1" colspan="1">0.0113962</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">98.9731</td><td align="center" rowspan="1" colspan="1">55.9383</td><td align="center" rowspan="1" colspan="1">18.1855</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">90.9335</td><td align="center" rowspan="1" colspan="1">57.6229</td><td align="center" rowspan="1" colspan="1">5.77804</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">98.525</td><td align="center" rowspan="1" colspan="1">80.3409</td><td align="center" rowspan="1" colspan="1">0.189017</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">103.311</td><td align="center" rowspan="1" colspan="1">60.1029</td><td align="center" rowspan="1" colspan="1">9.90685</td></tr><tr><td rowspan="5" align="center" colspan="1">7LD3</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">102.325</td><td align="center" rowspan="1" colspan="1">66.3654</td><td align="center" rowspan="1" colspan="1">9.57802</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">116.588</td><td align="center" rowspan="1" colspan="1">39.6037</td><td align="center" rowspan="1" colspan="1">1.85097</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">63.8847</td><td align="center" rowspan="1" colspan="1">56.3795</td><td align="center" rowspan="1" colspan="1">4.53461</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">130.194</td><td align="center" rowspan="1" colspan="1">78.0161</td><td align="center" rowspan="1" colspan="1">0.33005</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">148.673</td><td align="center" rowspan="1" colspan="1">53.5358</td><td align="center" rowspan="1" colspan="1">3.33969</td></tr></tbody></table></table-wrap></sec><sec id="s3-1-5"><title>3.1.5 The stability of the docked complexes studied by molecular dynamics (MD) simulation</title><p>Root Mean Square Deviation (RMSD) is a standard metric used to assess the structural changes of molecules during molecular dynamics simulations, reflecting the deviation between the molecule&#x02019;s conformation at each time step and its initial structure. This study&#x02019;s RMSD values remained around 1&#x000a0;nm, indicating a relatively stable binding state between Compound 5 and the 7LD3 protein. The maintenance of RMSD values around 1&#x000a0;nm suggests that no significant conformational changes occurred in the molecule during the simulation. The RMSD values of compound 5 with the 7LD3 protein remained relatively stable, with a relative variation of around 0.5 ns in <xref rid="F4" ref-type="fig">Figure 4</xref>. This relative stability in the binding state indicates an intense and persistent interaction.</p><fig position="float" id="F4"><label>FIGURE 4</label><caption><p>RMSD of Compound 5 with protein target (PDB ID: 7LD3) in 15000ps.</p></caption><graphic xlink:href="fphar-16-1467504-g004" position="float"/></fig><p>Compound 5 and the 7LD3 protein are promising candidates for further drug design and development efforts.</p><p>A stable binding state is crucial for drug design as it ensures reliable interactions between the molecule and the target protein, potentially enhancing the drug&#x02019;s efficacy and safety. Therefore, the analysis of RMSD values provides deeper insights into the interaction characteristics between Compound 5 and the 7LD3 protein, serving as important reference data for subsequent drug design and clinical research.</p></sec><sec id="s3-1-6"><title>3.1.6 The distribution of dynamic binding positions of molecules</title><p>Through the analysis of the binding frequency of molecules at different locations, preferred binding regions on the protein surface can be identified in <xref rid="s11" ref-type="sec">Supplementary Figure S1</xref>. Certain regions may exhibit a higher binding affinity for molecules, indicating potential drug-binding sites. The duration of molecule residence at different locations can assess the stability of the interaction between the molecule and the protein target. Prolonged residence at specific locations suggests a stable binding, whereas short residence times correspond to weak, transient interactions. Within the 15000ps simulation timeframe, the molecule&#x02019;s motion range, as illustrated in <xref rid="F5" ref-type="fig">Figure 5</xref>, indicates a relatively stable state at the binding site on the protein. Based on this binding site, molecular docking between the molecule and the protein target was conducted.</p><fig position="float" id="F5"><label>FIGURE 5</label><caption><p>2D and 3D diagrams of Compound 5 with protein target (PDB ID: 7LD3).</p></caption><graphic xlink:href="fphar-16-1467504-g005" position="float"/></fig></sec><sec id="s3-1-7"><title>3.1.7 Binding force analysis</title><p>In light of the Molecular dynamics (MD) simulation results, we performed a binding force analysis using Discovery Studio&#x02019;s receptor-ligand interaction calculation tool. In <xref rid="F5" ref-type="fig">Figure 5</xref>, the interactions between protein (PDB ID: 7LD3) and Compound 5 mainly comprised hydrogen bonds, Electrostatic and Hydrophobic. For hydrogen bonds, residue 91, residue 70, and residue 172 formed three conventional hydrogen bonds with bond lengths of 2.0&#x000c5; and 3.11&#x000c5;. Residue 265, residue 266, and residue 270 formed three carbon-hydrogen bonds. For Electrostatic: residue 124 formed one Pi-Anion bond. For Hydrophobic, residues 66, 87, 274, 171, 278, 180, and 250 formed four Pi-Alkyl bonds, one Pi-Sigma bond, and four Alkyl bonds.</p></sec><sec id="s3-1-8"><title>3.1.8 Protein subcellular localization</title><p>In <xref rid="T5" ref-type="table">Table 5</xref>, the predominant localization of THE ADENOSINE A1 RECEPTOR within the cytoplasm (71.87%) underscores its potential involvement in cellular interactions within this compartment. Consequently, Compound 5 is implicated in interacting with the protein within the cytoplasmic milieu. This localization pattern suggests that THE ADENOSINE A1 RECEPTOR may play pivotal roles in cytoplasmic signalling cascades, cellular metabolism, or other essential processes within this dynamic cellular region. The high proportion of THE ADENOSINE A1 RECEPTOR in the cytoplasm implies its significance in orchestrating cellular responses to extracellular stimuli or modulating intracellular signalling pathways critical for cell homeostasis. Therefore, understanding the interactions between Compound 5 and THE ADENOSINE A1 RECEPTOR in the cytoplasmic context holds promise for elucidating their functional implications and potential therapeutic applications in cellular processes governed by THE ADENOSINE A1 RECEPTOR-mediated signalling.</p><table-wrap position="float" id="T5"><label>TABLE 5</label><caption><p>Protein subcellular localization results.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Drug</th><th align="center" rowspan="1" colspan="1">Protein</th><th align="center" rowspan="1" colspan="1">Location (k = 23)</th><th align="center" rowspan="1" colspan="1">UniProt ID</th><th align="center" rowspan="1" colspan="1">PDB ID</th></tr></thead><tbody valign="top"><tr><td rowspan="3" align="center" colspan="1">Compound 5</td><td rowspan="3" align="center" colspan="1">The adenosine A1 receptor</td><td align="center" rowspan="1" colspan="1">Extra: 71.87%</td><td rowspan="3" align="center" colspan="1">P30542</td><td rowspan="3" align="center" colspan="1">7LD3</td></tr><tr><td align="center" rowspan="1" colspan="1">Plus 18.75%</td></tr><tr><td align="center" rowspan="1" colspan="1">Nucl: 6.25%<break/>also: 3.13%</td></tr></tbody></table></table-wrap><p>Compounds inhibit the activity of the human adenosine A1 receptor-Gi2 protein target and their molecular docking study. We identified compounds with significant inhibitory activity against the human adenosine A1 receptor-Gi2 protein through a comprehensive literature review. The research papers on these compounds have an impact factor greater than 10 (IF &#x0003e; 10).</p><p>Ultimately, we selected four compounds demonstrating notable inhibitory activity against this target, as summarized in <xref rid="T6" ref-type="table">Table 6</xref>. To further validate the inhibitory effects of these compounds, we employed molecular docking techniques, docking each of the four compounds with the 7LD3 target. The optimal docking conformations for each compound were identified and are detailed in <xref rid="T7" ref-type="table">Table 7</xref>.</p><table-wrap position="float" id="T6"><label>TABLE 6</label><caption><p>Structures against the human adenosine A1 receptor-Gi2-protein.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Compounds</th><th align="left" rowspan="1" colspan="1">Structural formula</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">6 (<xref rid="B10" ref-type="bibr">Draper-Joyce et al., 2021</xref>)</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2025-1467504_wc_tfx6.jpg"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">7 (<xref rid="B24" ref-type="bibr">Liu et al., 2019</xref>)</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2025-1467504_wc_tfx7.jpg"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">8 (<xref rid="B27" ref-type="bibr">Meibom et al., 2017</xref>)</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2025-1467504_wc_tfx8.jpg"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">9 (<xref rid="B42" ref-type="bibr">Vu et al., 2004</xref>)</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="FPHAR_fphar-2025-1467504_wc_tfx9.jpg"/>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T7"><label>TABLE 7</label><caption><p>Results of docking in protein target with compounds.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Target</th><th align="center" rowspan="1" colspan="1">compound</th><th align="center" rowspan="1" colspan="1">libdockscore</th><th align="center" rowspan="1" colspan="1">Absolute energy</th><th align="center" rowspan="1" colspan="1">Relative energy</th></tr></thead><tbody valign="top"><tr><td rowspan="4" align="center" colspan="1">7LD3</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">109.963</td><td align="center" rowspan="1" colspan="1">53.4481</td><td align="center" rowspan="1" colspan="1">5.32973</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">114.504</td><td align="center" rowspan="1" colspan="1">78.0218</td><td align="center" rowspan="1" colspan="1">5.11853</td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">76.097</td><td align="center" rowspan="1" colspan="1">97.4955</td><td align="center" rowspan="1" colspan="1">0.801548</td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">136.729</td><td align="center" rowspan="1" colspan="1">81.5171</td><td align="center" rowspan="1" colspan="1">2.3624</td></tr></tbody></table></table-wrap></sec><sec id="s3-1-9"><title>3.1.9 Pharmacophores construction</title><p>Leveraging insights into compound-target interactions, in <xref rid="T8" ref-type="table">Table 8</xref>, we systematically constructed 22 pharmacophore models. Subsequent scrutiny of our compound library involved meticulous assessment of fit values against these models. Notably, this process unearthed two pharmacophore models demonstrating robust compatibility with compound 10. Specifically, pharmacophore model Molecule7_03 exhibited a fit value of 3.07, while pharmacophore model Molecule7_04 displayed a fit value of 3.05, indicating their strong affinity for compound 10.</p><table-wrap position="float" id="T8"><label>TABLE 8</label><caption><p>Results of screening in pharmacophores with compounds.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Pharmacophores</th><th align="center" rowspan="1" colspan="1">Best docking pose</th><th align="center" rowspan="1" colspan="1">Fit value</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">Molecule7_01</td><td align="center" rowspan="1" colspan="1">Molecule9-2</td><td align="center" rowspan="1" colspan="1">1.30226</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule7_02</td><td align="center" rowspan="1" colspan="1">Molecule15-11</td><td align="center" rowspan="1" colspan="1">1.95561</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule7_03</td><td align="center" rowspan="1" colspan="1">Molecule10-4</td><td align="center" rowspan="1" colspan="1">3.07071</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule7_04</td><td align="center" rowspan="1" colspan="1">Molecule10-1</td><td align="center" rowspan="1" colspan="1">3.0506</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule7_05</td><td align="center" rowspan="1" colspan="1">Molecule13-12</td><td align="center" rowspan="1" colspan="1">2.47614</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule7_06</td><td align="center" rowspan="1" colspan="1">Molecule8-6</td><td align="center" rowspan="1" colspan="1">2.01747</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule8_01</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule8_02</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule8_03</td><td align="center" rowspan="1" colspan="1">Molecule12-8</td><td align="center" rowspan="1" colspan="1">2.09077</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule8_04</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule8_05</td><td align="center" rowspan="1" colspan="1">Molecule12-2</td><td align="center" rowspan="1" colspan="1">1.19133</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule8_06</td><td align="center" rowspan="1" colspan="1">Molecule3-10</td><td align="center" rowspan="1" colspan="1">1.05892</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule9_01</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule9_02</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule9_03</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule9_04</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule9_05</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule9_06</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule9_07</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule9_08</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule9_09</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Molecule9_10</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap></sec></sec><sec id="s3-2"><title>3.2 Chemistry</title><sec id="s3-2-1"><title>3.2.1 Synthesis route of molecule 10</title><p>Compound 1 was transformed into compound two as (<sup>1</sup>H NMR is shown in <xref rid="s11" ref-type="sec">Supplementary Figure S2</xref>) via amide condensation. Subsequently, compound 2 underwent nucleophilic substitution with 1,4-dichloropyrimidine to yield compound 3(<sup>1</sup>H NMR is shown in <xref rid="s11" ref-type="sec">Supplementary Figure S3</xref>). Compound 3 was further subjected to nucleophilic substitution with 3-hydroxy-4-methoxybenzaldehyde to obtain the final product, molecule 10(<sup>1</sup>H NMR and <sup>13</sup>C NMR, respectively are shown in <xref rid="s11" ref-type="sec">Supplementary Figure S4</xref> and <xref rid="s11" ref-type="sec">Supplementary Figure S5</xref>, the LCMS of molecule 10 is shown in <xref rid="s11" ref-type="sec">Supplementary Figure S6</xref>). For detailed synthetic procedures, refer to <xref rid="s11" ref-type="sec">Supplementary 2.1</xref> Chemistry.</p></sec></sec><sec id="s3-3"><title>3.3 Activity</title><sec id="s3-3-1"><title>3.3.1 <italic>In vitro</italic> activity assay</title><p>We conducted an MTT assay to evaluate the biological activity of compound 10, using 5-fluorouracil (5-Fu) as a positive control. The experimental results demonstrated that compound 10 significantly inhibits breast cancer cells, as shown in <xref rid="T9" ref-type="table">Table 9</xref>. The IC50 value of compound 10 was determined to be 0.032 &#x000b1; 0.026&#x000a0;&#x000b5;M (The database is shown in <xref rid="s11" ref-type="sec">Supplementary Table S9</xref>), indicating a potent inhibitory activity at relatively low concentrations. These findings suggest that compound 10 possesses promising anti-breast cancer properties, providing a basis for further pharmacological studies and development. It is important to acknowledge that the biological activity of compound 10 was tested only on the MCF-7 breast cancer cell line. While these results are promising, they are limited to this particular cell type, which may not fully represent the heterogeneity of breast cancer. Future studies should include additional cell lines, such as MDA-MB cells, to assess the broader efficacy of compound 10 across different breast cancer subtypes and provide a more comprehensive evaluation of its potential therapeutic value. The detailed experimental procedures for the <italic>in vitro</italic> antitumor activity assay are provided in <xref rid="s11" ref-type="sec">Supplementary 3.1</xref>.</p><table-wrap position="float" id="T9"><label>TABLE 9</label><caption><p>MCF-7 cell viability and IC50 analysis.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Compounds</th><th align="left" rowspan="1" colspan="1">IC50 (&#x000b5;M)</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">1 (<xref rid="B22" ref-type="bibr">Khan et al., 2022</xref>)</td><td align="left" rowspan="1" colspan="1">3.4</td></tr><tr><td align="left" rowspan="1" colspan="1">2 (<xref rid="B4" ref-type="bibr">Benedekovi&#x00107; et al., 2020</xref>)</td><td align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">3 (<xref rid="B31" ref-type="bibr">Nejat et al., 2018a</xref>)</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">4 (<xref rid="B38" ref-type="bibr">Tamizharasan et al., 2020</xref>)</td><td align="left" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" rowspan="1" colspan="1">5 (<xref rid="B20" ref-type="bibr">Ihmaid et al., 2022</xref>)</td><td align="left" rowspan="1" colspan="1">3.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Molecule 10</td><td align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">5-FU (Positive cotrol)</td><td align="left" rowspan="1" colspan="1">0.45</td></tr></tbody></table><table-wrap-foot><fn><p>Note: 1. IC50 values were calculated using nonlinear regression analysis. 2. Positive control: 5-FU (5-Fluorouracil).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3-4"><title>3.4 Role of the adenosine A1 receptor in cancer signaling pathways and its therapeutic potential</title><p>In the context of cancer, THE ADENOSINE A1 RECEPTOR&#x02019;s signalling mechanisms contribute to the suppression of tumour growth and metastasis. It achieves this by modulating the tumour microenvironment, enhancing antitumor immune responses, and interfering with key processes such as angiogenesis and cellular survival. Activation of THE ADENOSINE A1 RECEPTOR has been linked to the inhibition of cancer cell growth and induction of apoptosis through various molecular pathways, including the suppression of NF-&#x003ba;B activity, a key driver of inflammation and tumorigenesis.</p><p>This study contributes significantly to understanding THE ADENOSINE A1 RECEPTOR&#x02019;s therapeutic potential by identifying key binding sites and interactions through molecular docking and dynamics simulations. Our findings highlight that compound 10 interacts favourably with THE ADENOSINE A1 RECEPTOR, suggesting its potential as a targeted therapy for breast cancer. By exploring THE ADENOSINE A1 RECEPTOR&#x02019;s involvement in cancer signalling pathways, this study not only validates its role in tumour suppression but also opens the door for further research into THE ADENOSINE A1 RECEPTOR-targeted therapeutic agents that could complement existing cancer treatments.</p></sec></sec><sec sec-type="conclusion" id="s4"><title>4 Conclusion</title><p>In conclusion, this study employed a comprehensive bioinformatics and computational chemistry approach to identify novel targets and active compounds for breast cancer treatment. Initial screening and intersection analyses revealed that THE ADENOSINE A1 RECEPTOR was a critical protein target. Molecular docking and molecular dynamics (MD) simulations demonstrated the stable binding of Compound 5 to the 7LD3 protein, suggesting its potential as a lead compound. Guided by a pharmacophore model constructed from the binding interactions of active compounds (6&#x02013;9), we designed and synthesized Molecule 10, which exhibited significant antitumor activity against MCF-7 cells, with an IC50 value of 0.032 &#x000b5;M, underscoring its potential as a promising therapeutic candidate.</p><p>Furthermore, 500 target proteins were initially screened using the SwissTargetPrediction Database, and Family A&#x000a0;G protein-coupled receptors were found to rank among the top three targets. An intersection analysis using Venny 2.1.0 online software identified two common targets for three compounds, providing further insights into their shared potential in breast cancer therapy. Protein screening through the PubChem Database highlighted the significant importance of the ADENOSINE A1 RECEPTOR protein, with lower relevance for ADORA2A.</p><p>We analyzed the interaction characteristics between the compounds and proteins, identifying five compounds with significant interactions. Given the substantial spatial differences among these compounds, we constructed 22 pharmacophore models and screened a custom-designed compound library, identifying molecules with strong potential for further development.</p><p>In future studies, Compound 10 will be tested in animal models to evaluate its vivo efficacy and potential therapeutic benefits in breast cancer treatment. Additionally, efforts will be made to optimize its pharmacokinetic properties, including bioavailability and metabolic stability, to enhance its clinical potential. This study primarily relied on <italic>in vitro</italic> assays and computational predictions, which may not fully capture the complexity of biological systems. The exclusive use of MCF-7 cells and computational models may limit the generalizability of the findings. Therefore, further studies incorporating additional <italic>in vitro</italic> models and <italic>in vivo</italic> validation are essential to confirm the therapeutic potential of the identified compounds.</p><p>(&#x02160;) HOBT, EDCI, DMF, r.t., 3.5 h; (&#x02161;) K<sub>2</sub>CO<sub>3</sub>, DMF, 80&#x000b0;C, 6 h; (&#x02162;) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 100&#x000b0;C. Through a three-step synthesis, we obtained molecule 10, which demonstrated promising antitumor activity against MCF-7 cells in MTT assays, with an IC50 value of 0.032&#x000a0;&#x000b5;M. This study provides important theoretical support and candidate compounds for designing and developing therapeutics in breast cancer treatment.</p></sec></body><back><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref rid="s11" ref-type="sec">supplementary material</xref>.</p></sec><sec sec-type="ethics-statement" id="s6"><title>Ethics statement</title><p>No human studies are presented in the manuscript. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>JX: Writing &#x02013; original draft, Writing &#x02013; review and editing. XL: Writing &#x02013; review and editing. YJ: Writing &#x02013; review and editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec id="s11"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2025.1467504/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fphar.2025.1467504/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="DataSheet1.pdf"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adams</surname><given-names>M.</given-names></name><name><surname>Louise</surname><given-names>J. J.</given-names></name><name><surname>Rosemary</surname><given-names>A.</given-names></name><name><surname>Pringle</surname><given-names>J. H.</given-names></name><name><surname>Bell</surname><given-names>S. C.</given-names></name></person-group> (<year>2002</year>). <article-title>Changes in tenascin-C isoform expression in invasive and preinvasive breast disease</article-title>. <source>Cancer Res.</source>
<volume>62</volume>, <fpage>3289</fpage>&#x02013;<lpage>3297</lpage>.<pub-id pub-id-type="pmid">12036947</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Azimian</surname><given-names>F.</given-names></name><name><surname>Dastmalchi</surname><given-names>S.</given-names></name></person-group> (<year>2023</year>). <article-title>Recent advances in structural modification strategies for lead optimization of tyrosine kinase inhibitors to explore novel anticancer agents</article-title>. <source>Curr. Med. Chem.</source>
<volume>30</volume>, <fpage>2734</fpage>&#x02013;<lpage>2761</lpage>. <pub-id pub-id-type="doi">10.2174/0929867329666220920092908</pub-id>
<pub-id pub-id-type="pmid">36125833</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baroroh</surname><given-names>U.</given-names></name><name><surname>Biotek</surname><given-names>M.</given-names></name><name><surname>Muscifa</surname><given-names>Z. S.</given-names></name><name><surname>Destiarani</surname><given-names>W.</given-names></name><name><surname>Rohmatullah</surname><given-names>F. G.</given-names></name><name><surname>Yusuf</surname><given-names>M.</given-names></name></person-group> (<year>2023</year>). <source>Molecular interaction analysis and visualization of protein-ligand docking using Biovia Discovery Studio Visualizer</source>, <volume>2</volume>, <fpage>22</fpage>&#x02013;<lpage>30</lpage>.</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benedekovi&#x00107;</surname><given-names>G.</given-names></name><name><surname>Popsavin</surname><given-names>M.</given-names></name><name><surname>Kova&#x0010d;evi&#x00107;</surname><given-names>I.</given-names></name><name><surname>Koji&#x00107;</surname><given-names>V.</given-names></name><name><surname>Rodi&#x00107;</surname><given-names>M.</given-names></name><name><surname>Popsavin</surname><given-names>V.</given-names></name></person-group> (<year>2020</year>). <article-title>Synthesis, antiproliferative activity and SAR analysis of (-)-cleistenolide and analogues</article-title>, <source>Eur. J. Med. Chem.</source>, <volume>202</volume>
<fpage>112597</fpage>, <pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112597</pub-id>
<pub-id pub-id-type="pmid">32653698</pub-id>
</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benedekovic</surname><given-names>G.</given-names></name><name><surname>Popsavin</surname><given-names>M.</given-names></name><name><surname>Kovacevic</surname><given-names>I.</given-names></name><name><surname>Kojic</surname><given-names>V.</given-names></name><name><surname>Rodic</surname><given-names>M.</given-names></name><name><surname>Popsavin</surname><given-names>V.</given-names></name></person-group> (<year>2020</year>). <article-title>Synthesis, antiproliferative activity and SAR analysis of (-)-cleistenolide and analogues</article-title>. <source>Eur. J. Med. Chem.</source>
<volume>202</volume>, <fpage>112597</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112597</pub-id>
<pub-id pub-id-type="pmid">32653698</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bheeram</surname><given-names>V. R.</given-names></name><name><surname>Malla</surname><given-names>R. R.</given-names></name><name><surname>Kumari</surname><given-names>S.</given-names></name><name><surname>Saha</surname><given-names>A.</given-names></name><name><surname>Mukkamala</surname><given-names>S. B.</given-names></name></person-group> (<year>2019</year>). <article-title>Cytotoxic Effect of Photoluminescent RE3+ doped Ca3(PO4)2 nanorods on breast cancer cell lines</article-title>. <source>IRBM</source>
<volume>40</volume>, <fpage>270</fpage>&#x02013;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1016/j.irbm.2019.05.001</pub-id>
</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bohyun</surname><given-names>M.</given-names></name><name><surname>Yong Joo</surname><given-names>P.</given-names></name><name><surname>Gi Ho</surname><given-names>S.</given-names></name><name><surname>Yunmi</surname><given-names>L.</given-names></name><name><surname>Ki Hyun</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>Synthesis and antitumor activity of (&#x02212;)-bassianolide in MDA-MB 231 breast cancer cells through cell cycle arrest</article-title>. <source>Bioorg. Chem.</source>
<volume>69</volume>, <fpage>64</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2016.09.008</pub-id>
<pub-id pub-id-type="pmid">27676608</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Devendar</surname><given-names>P.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Srinivas</surname><given-names>K. V. N. S.</given-names></name><name><surname>Luqman</surname><given-names>S.</given-names></name><name><surname>Sarfaraz</surname><given-names>A.</given-names></name><name><surname>Zehra</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation</article-title>. <source>Eur. J. Med. Chem.</source>
<volume>87</volume>, <fpage>735</fpage>&#x02013;<lpage>744</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2014.10.013</pub-id>
<pub-id pub-id-type="pmid">25305717</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dorrani</surname><given-names>H.</given-names></name><name><surname>Mohebbi</surname><given-names>A. J. J. o.E. T.</given-names></name></person-group> (<year>2023</year>). <source>A comparative study of TIP4P-2005, SPC/E, SPC, and TIP3P-Ew models for predicting water transport coefficients using EMD and NEMD simulations</source>, <volume>32</volume>, <fpage>138</fpage>&#x02013;<lpage>161</lpage>.</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Draper-Joyce</surname><given-names>C. J.</given-names></name><name><surname>Bhola</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Bhattarai</surname><given-names>A.</given-names></name><name><surname>Nguyen</surname><given-names>A. T.</given-names></name><name><surname>Cowie-Kent</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia</article-title>. <source>Nature</source>
<volume>597</volume>, <fpage>571</fpage>&#x02013;<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03897-2</pub-id>
<pub-id pub-id-type="pmid">34497422</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dulong</surname><given-names>C.</given-names></name><name><surname>Fang</surname><given-names>Y. J.</given-names></name><name><surname>Gest</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>M. H.</given-names></name><name><surname>Patte-Mensah</surname><given-names>C.</given-names></name><name><surname>Mensah-Nyagan</surname><given-names>A. G.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>The small GTPase RhoA regulates the expression and function of the sodium channel Nav1.5 in breast cancer cells</article-title>. <source>Int. J. Oncol.</source>
<volume>44</volume>, <fpage>539</fpage>&#x02013;<lpage>547</lpage>. <comment>5 in breast cancer cells</comment>. <pub-id pub-id-type="doi">10.3892/ijo.2013.2214</pub-id>
<pub-id pub-id-type="pmid">24337141</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Gahbauer</surname><given-names>S.</given-names></name><name><surname>Correy</surname><given-names>G. J.</given-names></name><name><surname>Schuller</surname><given-names>M.</given-names></name><name><surname>Ferla</surname><given-names>M. P.</given-names></name><name><surname>Doruk</surname><given-names>Y. U.</given-names></name><name><surname>Rachman</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2023</year>). <source>Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2</source>, <fpage>120</fpage>. <comment>e2212931120</comment>.</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gerhard</surname><given-names>R.</given-names></name><name><surname>Kerstin</surname><given-names>B.</given-names></name><name><surname>Anja</surname><given-names>W.</given-names></name><name><surname>Brigitte</surname><given-names>K.</given-names></name><name><surname>Silke</surname><given-names>B.</given-names></name><name><surname>Ingo</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Synthesis and biological activities of transition metal complexes based on acetylsalicylic acid as neo-anticancer agents</article-title>. <source>J. Med. Chem.</source>
<volume>53</volume>, <fpage>6889</fpage>&#x02013;<lpage>6898</lpage>. <pub-id pub-id-type="doi">10.1021/jm101019j</pub-id>
<pub-id pub-id-type="pmid">20857911</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2024</year>). <source>Thwarting resistance: MgrA inhibition with methylophiopogonanone a unveils a new battlefront against S. aureus</source>, <volume>10 15</volume>.</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haiwen</surname><given-names>Z.</given-names></name><name><surname>Solomon</surname><given-names>V. R.</given-names></name><name><surname>Changkun</surname><given-names>H.</given-names></name><name><surname>Gerardo</surname><given-names>U.</given-names></name><name><surname>Hoyun</surname><given-names>L.</given-names></name></person-group> (<year>2007</year>). <article-title>Synthesis and <italic>in vitro</italic> cytotoxicity evaluation of 4-aminoquinoline derivatives</article-title>. <source>Biomed. &#x00026; Pharmacother.</source>
<pub-id pub-id-type="doi">10.1016/j.biopha.2007.04.007</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herdiana</surname><given-names>Y.</given-names></name><name><surname>Sriwidodo</surname><given-names>S.</given-names></name><name><surname>Sofian</surname><given-names>F. F.</given-names></name><name><surname>Wilar</surname><given-names>G.</given-names></name><name><surname>Diantini</surname><given-names>A. J. M.</given-names></name></person-group> (<year>2023</year>). <source>Nanoparticle-based antioxidants in stress signaling and programmed cell death in breast cancer treatment</source>, <volume>28</volume>, <fpage>5305</fpage>.</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holger</surname><given-names>B.</given-names></name><name><surname>Sara</surname><given-names>K.</given-names></name><name><surname>Ulrike</surname><given-names>S.-B.</given-names></name><name><surname>Claudia</surname><given-names>C.</given-names></name><name><surname>Alexandra</surname><given-names>S.</given-names></name><name><surname>Stefanie</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer</article-title>. <source>Breast Cancer Res.</source>
<volume>14</volume>, <fpage>R30</fpage>. <pub-id pub-id-type="doi">10.1186/bcr3115</pub-id>
<pub-id pub-id-type="pmid">22333315</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>I.-M.</given-names></name><name><surname>Lin</surname><given-names>B.</given-names></name><name><surname>Mahbub</surname><given-names>H.</given-names></name><name><surname>Carter</surname><given-names>Z.</given-names></name><name><surname>Jebur</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Field demonstration of intensified membrane distillation for treating oilfield produced waters from unconventional wells</article-title>. <source>Desalination</source>
<volume>564</volume>, <fpage>116771</fpage>. <pub-id pub-id-type="doi">10.1016/j.desal.2023.116771</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huzaifa</surname><given-names>U.</given-names></name><name><surname>Doga</surname><given-names>K.</given-names></name><name><surname>Nahit</surname><given-names>R.</given-names></name></person-group> (<year>2018</year>). <article-title>Biosynthesis of zinc oxide nanoparticles using Albizia lebbeck stem bark, and evaluation of its antimicrobial, antioxidant, and cytotoxic activities on human breast cancer cell lines</article-title>. <source>Int. J. Nanomedicine</source>
<volume>Vol. 14</volume>, <fpage>87</fpage>&#x02013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.2147/ijn.s186888</pub-id>
</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ihmaid</surname><given-names>S. K.</given-names></name><name><surname>Aljuhani</surname><given-names>A.</given-names></name><name><surname>Alsehli</surname><given-names>M.</given-names></name><name><surname>Rezki</surname><given-names>N.</given-names></name><name><surname>Alawi</surname><given-names>A.</given-names></name><name><surname>Aldhafiri</surname><given-names>A. J.</given-names></name><etal/></person-group> (<year>2022</year>). <source>Discovery of triaromatic flexible agents bearing 1, 2, 3-Triazole with selective and potent anti-breast cancer activity and CDK9 inhibition supported by molecular dynamics</source>, <volume>1249</volume>.<fpage>131568</fpage>.</mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jia</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Qi</surname><given-names>M.</given-names></name></person-group> (<year>2023</year>). <article-title>Design and synthesis of cyclopropanedicarboxamide-based hybrid drugs</article-title>. <source>Contemporary Chemical Research</source>, <fpage>179</fpage>&#x02013;<lpage>181</lpage>.</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jojart</surname><given-names>R.</given-names></name><name><surname>Tahaei</surname><given-names>S. A. S.</given-names></name><name><surname>Trungel-Nagy</surname><given-names>P.</given-names></name><name><surname>Kele</surname><given-names>Z.</given-names></name><name><surname>Minorics</surname><given-names>R.</given-names></name><name><surname>Paragi</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Synthesis and evaluation of anticancer activities of 2- or 4-substituted 3-(N-benzyltriazolylmethyl)-13&#x003b1;-oestrone derivatives</article-title>. <source>J. Enzyme Inhib. Med. Chem.</source>
<volume>36</volume>, <fpage>58</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1080/14756366.2020.1838500</pub-id>
<pub-id pub-id-type="pmid">33121276</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khan</surname><given-names>M. K.</given-names></name><name><surname>Siddiqui</surname><given-names>H.</given-names></name><name><surname>Sharif</surname><given-names>R.</given-names></name><name><surname>Guzel</surname><given-names>M.</given-names></name><name><surname>Wahab</surname><given-names>A.-t.</given-names></name><name><surname>Yousuf</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2022</year>). <source>Lamotrigine derivatives&#x02010;synthesis, anti&#x02010;cancer, and anti&#x02010;MDR&#x02010;bacterial activities</source>, <volume>1264</volume>.<fpage>133277</fpage>.</mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zou</surname><given-names>Q.</given-names></name><name><surname>Yuan</surname><given-names>L. J. M. T.-N. A.</given-names></name></person-group> (<year>2023</year>). <article-title>A review from biological mapping to computation-based subcellular localization</article-title>. <source>Mol. Ther. Nucleic Acids</source>
<volume>32</volume>, <fpage>507</fpage>&#x02013;<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1016/j.omtn.2023.04.015</pub-id>
<pub-id pub-id-type="pmid">37215152</pub-id>
</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>G.</given-names></name><name><surname>Liang</surname><given-names>R.</given-names></name><name><surname>Chung</surname><given-names>L. W.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Asymmetric total synthesis of cerorubenic acid-III</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>141</volume>, <fpage>2872</fpage>&#x02013;<lpage>2877</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.8b12647</pub-id>
<pub-id pub-id-type="pmid">30721058</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lv</surname><given-names>Y.</given-names></name><name><surname>Mou</surname><given-names>Y.</given-names></name><name><surname>Su</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2023</year>). <source>The inhibitory effect and mechanism of Resina Draconis on the proliferation of MCF-7 breast cancer cells: a network pharmacology-based analysis</source>, <volume>13</volume>, <fpage>3816</fpage>.</mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maria</surname><given-names>P.</given-names></name><name><surname>Wukun</surname><given-names>L.</given-names></name><name><surname>Adelheid</surname><given-names>H.</given-names></name><name><surname>Ulrich</surname><given-names>A.</given-names></name><name><surname>Ronald</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Synthesis, characterization and <italic>in vitro</italic> antitumour activity of a series of novel platinum(II) complexes bearing Schiff base ligands</article-title>. <source>Eur. J. Med. Chem.</source>
<volume>53</volume>, <fpage>168</fpage>&#x02013;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2012.03.053</pub-id>
<pub-id pub-id-type="pmid">22534185</pub-id>
</mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meibom</surname><given-names>D.</given-names></name><name><surname>Albrecht&#x02010;K&#x000fc;pper</surname><given-names>B.</given-names></name><name><surname>Diedrichs</surname><given-names>N.</given-names></name><name><surname>H&#x000fc;bsch</surname><given-names>W.</given-names></name><name><surname>Kast</surname><given-names>R.</given-names></name><name><surname>Kr&#x000e4;mer</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Neladenoson bialanate hydrochloride: a prodrug of a partial adenosine A1 receptor agonist for the chronic treatment of heart diseases</article-title>. <volume>12</volume>
<fpage>728</fpage>&#x02013;<lpage>737</lpage>.</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Menezes</surname><given-names>T. M.</given-names></name><name><surname>da Silva Neto</surname><given-names>A. M.</given-names></name><name><surname>Gubert</surname><given-names>P.</given-names></name><name><surname>Neves</surname><given-names>J. L. J. J. o.M. L.</given-names></name></person-group> (<year>2021</year>). <source>Effects of human serum albumin glycation on the interaction with the tyrosine kinase inhibitor pazopanib unveiled by multi-spectroscopic and bioinformatic tools</source>, <volume>340</volume>.<fpage>116843</fpage>.</mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakhjiri</surname><given-names>M.</given-names></name><name><surname>Safavi</surname><given-names>M.</given-names></name><name><surname>Alipour</surname><given-names>E.</given-names></name><name><surname>Emami</surname><given-names>S.</given-names></name><name><surname>Atash</surname><given-names>A. F.</given-names></name><name><surname>Jafari-Zavareh</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Asymmetrical 2,6-bis(benzylidene)cyclohexanones: synthesis, cytotoxic activity and QSAR study</article-title>. <source>Eur. J. Med. Chem.</source>
<volume>50</volume>, <fpage>113</fpage>&#x02013;<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2012.01.045</pub-id>
<pub-id pub-id-type="pmid">22341788</pub-id>
</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Neagu</surname><given-names>A.-N.</given-names></name><name><surname>Whitham</surname><given-names>D.</given-names></name><name><surname>Bruno</surname><given-names>P.</given-names></name><name><surname>Morrissiey</surname><given-names>H.</given-names></name><name><surname>Darie</surname><given-names>C. A.</given-names></name><name><surname>Darie</surname><given-names>C. C. J. M.</given-names></name></person-group> (<year>2023</year>). <source>Omics-based investigations of breast cancer</source>, <volume>28</volume>, <fpage>4768</fpage>.</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nejat</surname><given-names>R.</given-names></name><name><surname>Mahjoub</surname><given-names>M. A.</given-names></name><name><surname>Hekmatian</surname><given-names>Z.</given-names></name><name><surname>Javidi</surname><given-names>M. A.</given-names></name><name><surname>Babashah</surname><given-names>S.</given-names></name></person-group> (<year>2018a</year>). <source>Zeolite-catalyzed synthesis of pyrazolo [1, 2-a][1, 2, 4] triazole-1, 3-dione derivatives as anti-breast cancer agents</source>, <volume>15</volume>, <fpage>1133</fpage>&#x02013;<lpage>1143</lpage>.</mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nejat</surname><given-names>R.</given-names></name><name><surname>Mahjoub</surname><given-names>M. A.</given-names></name><name><surname>Hekmatian</surname><given-names>Z.</given-names></name><name><surname>Javidi</surname><given-names>M. A.</given-names></name><name><surname>Babashah</surname><given-names>S.</given-names></name></person-group> (<year>2018b</year>). <article-title>Zeolite-catalyzed synthesis of pyrazolo[1,2-a] [1,2,4]triazole-1,3-dione derivatives as anti-breast cancer agents</article-title>. <source>J. Iran. Chem. Soc.</source>
<volume>15</volume>, <fpage>1133</fpage>&#x02013;<lpage>1143</lpage>. <pub-id pub-id-type="doi">10.1007/s13738-018-1310-6</pub-id>
</mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noor</surname><given-names>N. S.</given-names></name><name><surname>Kaus</surname><given-names>N. H. M.</given-names></name><name><surname>Szewczuk</surname><given-names>M. R.</given-names></name><name><surname>Hamid</surname><given-names>S. B. S.</given-names></name></person-group> (<year>2021</year>). <article-title>Formulation, characterization and cytotoxicity effects of novel thymoquinone-PLGA-PF68 nanoparticles</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>22</volume>, <fpage>9420</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22179420</pub-id>
<pub-id pub-id-type="pmid">34502328</pub-id>
</mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>&#x000d6;zgen</surname><given-names>&#x000d6;.</given-names></name><name><surname>&#x000c7;etin</surname><given-names>&#x00130;.</given-names></name><name><surname>Atalar</surname><given-names>F.</given-names></name><name><surname>Top&#x000e7;ul</surname><given-names>M. R. J. C.</given-names></name><name><surname>Biology</surname><given-names>M.</given-names></name></person-group> (<year>2025</year>). <article-title>Alpha-mangostin and nab-paclitaxel in breast cancer cell models: improved antitumor efficacy through combination therapy</article-title>. <source>Cell. Mol. Biol.</source>
<volume>71</volume>, <fpage>52</fpage>&#x02013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.14715/cmb/2025.70.1.6</pub-id>
</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rebeka</surname><given-names>J.</given-names></name><name><surname>Seyyed Ashkan Senobar</surname><given-names>T.</given-names></name><name><surname>P&#x000e9;ter</surname><given-names>T.-N.</given-names></name><name><surname>Zolt&#x000e1;n</surname><given-names>K.</given-names></name><name><surname>Ren&#x000e1;ta</surname><given-names>M.</given-names></name><name><surname>G&#x000e1;bor</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Synthesis and evaluation of anticancer activities of 2- or 4-substituted 3-(N-benzyltriazolylmethyl)-13&#x003b1;-oestrone derivatives</article-title>. <source>J. Enzyme inhibition Med. Chem.</source>
<volume>36</volume>, <fpage>58</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1080/14756366.2020.1838500</pub-id>
</mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Satish Kumar</surname><given-names>V.</given-names></name><name><surname>Rajkiran Reddy</surname><given-names>B.</given-names></name><name><surname>Sudip</surname><given-names>M.</given-names></name><name><surname>Purushotham</surname><given-names>U.</given-names></name><name><surname>Subbaiah</surname><given-names>G.</given-names></name><name><surname>Gurava Reddy</surname><given-names>A. V.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Novel biosynthesized gold nanoparticles as anti-cancer agents against breast cancer: synthesis, biological evaluation, molecular modelling studies</article-title>. <source>Biomater. Adv.</source>
<pub-id pub-id-type="doi">10.1016/j.msec.2019.01.123</pub-id>
</mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sihombing</surname><given-names>I. N. N.</given-names></name><name><surname>Arsianti</surname><given-names>A. J. J. o.P.</given-names></name><name><surname>Research</surname><given-names>P.</given-names></name></person-group> (<year>2024</year>). <article-title>Network pharmacology prediction and molecular docking analysis on the mechanism of eugenol as a candidate against estrogen receptor-positive breast cancer</article-title>. <volume>12</volume>
<fpage>837</fpage>&#x02013;<lpage>851</lpage>.</mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tamizharasan</surname><given-names>N.</given-names></name><name><surname>Gajendran</surname><given-names>C.</given-names></name><name><surname>Kristam</surname><given-names>R.</given-names></name><name><surname>Sulochana</surname><given-names>S. P.</given-names></name><name><surname>Sivanandhan</surname><given-names>D.</given-names></name><name><surname>Mullangi</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Discovery and optimization of novel phenyldiazepine and pyridodiazepine based Aurora kinase inhibitors</article-title>, <source>Bioorg. Chem.</source>, <volume>99</volume>
<fpage>103800</fpage>, <pub-id pub-id-type="doi">10.1016/j.bioorg.2020.103800</pub-id>
<pub-id pub-id-type="pmid">32283344</pub-id>
</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Tauro</surname><given-names>S.</given-names></name><name><surname>Dhokchawle</surname><given-names>B.</given-names></name><name><surname>Nahar</surname><given-names>D.</given-names></name><name><surname>Nadar</surname><given-names>S.</given-names></name><name><surname>Thakor</surname><given-names>E.</given-names></name><name><surname>Mohite</surname><given-names>P. J. D. D. S.</given-names></name></person-group> (<year>2025</year>). <source>Target-based vs phenotypic drug discovery: opportunities and challenges with evidence-based application</source>, <fpage>25</fpage>&#x02013;<lpage>45</lpage>.</mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomas</surname><given-names>W.</given-names></name><name><surname>Ingo</surname><given-names>O.</given-names></name><name><surname>Brigitte</surname><given-names>K.</given-names></name><name><surname>Petra</surname><given-names>S.</given-names></name><name><surname>Daniela</surname><given-names>S.</given-names></name><name><surname>Thierry</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Synthesis and pharmacological evaluation of 1H-imidazoles as ligands for the estrogen receptor and cytotoxic inhibitors of the cyclooxygenase</article-title>. <source>J. Med. Chem.</source>
<volume>48</volume>, <fpage>6516</fpage>&#x02013;<lpage>6521</lpage>. <pub-id pub-id-type="doi">10.1021/jm050190u</pub-id>
<pub-id pub-id-type="pmid">16190777</pub-id>
</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vieira</surname><given-names>I. H. P.</given-names></name><name><surname>Botelho</surname><given-names>E. B.</given-names></name><name><surname>de Souza Gomes</surname><given-names>T. J.</given-names></name><name><surname>Kist</surname><given-names>R.</given-names></name><name><surname>Caceres</surname><given-names>R. A.</given-names></name><name><surname>Zanchi</surname><given-names>F.</given-names></name></person-group> (<year>2023</year>). <article-title>Visual dynamics: a WEB application for molecular dynamics simulation using GROMACS</article-title>, <source>BMC Bioinforma.</source>, <volume>24</volume>
<fpage>107</fpage>, <pub-id pub-id-type="doi">10.1186/s12859-023-05234-y</pub-id>
</mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vu</surname><given-names>C. B.</given-names></name><name><surname>Peng</surname><given-names>B.</given-names></name><name><surname>Kumaravel</surname><given-names>G.</given-names></name><name><surname>Smits</surname><given-names>G.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Phadke</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Piperazine derivatives of [1, 2, 4] triazolo [1, 5-a] [1, 3, 5] triazine as potent and selective adenosine A2a receptor antagonists</article-title>. <source>J. Med. Chem.</source>
<volume>47</volume>, <fpage>4291</fpage>&#x02013;<lpage>4299</lpage>. <pub-id pub-id-type="doi">10.1021/jm0498405</pub-id>
<pub-id pub-id-type="pmid">15294001</pub-id>
</mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wukun</surname><given-names>L.</given-names></name><name><surname>Kerstin</surname><given-names>B.</given-names></name><name><surname>Maria</surname><given-names>P.</given-names></name><name><surname>Adelheid</surname><given-names>H.</given-names></name><name><surname>Ulrich</surname><given-names>A.</given-names></name><name><surname>Ronald</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Synthesis, characterization, and <italic>in vitro</italic> studies of bis[1,3-diethyl-4,5-diarylimidazol-2-ylidene]gold(I/III) complexes</article-title>. <source>J. Med. Chem.</source>
<volume>55</volume>, <fpage>3713</fpage>&#x02013;<lpage>3724</lpage>. <pub-id pub-id-type="doi">10.1021/jm3000196</pub-id>
<pub-id pub-id-type="pmid">22424185</pub-id>
</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wukun</surname><given-names>L.</given-names></name><name><surname>Kerstin</surname><given-names>B.</given-names></name><name><surname>Maria</surname><given-names>P.</given-names></name><name><surname>Ulrich</surname><given-names>A.</given-names></name><name><surname>Adelheid</surname><given-names>H.</given-names></name><name><surname>Ronald</surname><given-names>G.</given-names></name></person-group> (<year>2011</year>). <article-title>NHC gold halide complexes derived from 4,5-diarylimidazoles: synthesis, structural analysis, and pharmacological investigations as potential antitumor agents</article-title>. <source>J. Med. Chem.</source>
<volume>54</volume>, <fpage>8605</fpage>&#x02013;<lpage>8615</lpage>. <pub-id pub-id-type="doi">10.1021/jm201156x</pub-id>
<pub-id pub-id-type="pmid">22091836</pub-id>
</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zaremba</surname><given-names>A. A.</given-names></name><name><surname>Zaremba</surname><given-names>P. Y.</given-names></name><name><surname>Zahorodnia</surname><given-names>S. D. J. S. R.</given-names></name></person-group> (<year>2023</year>). <article-title>
<italic>In silico</italic> study of HASDI (high-affinity selective DNA intercalator) as a new agent capable of highly selective recognition of the DNA sequence</article-title>. <source>DNA Seq.</source>
<volume>13</volume>, <fpage>5395</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-023-32595-4</pub-id>
</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Yue</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2024</year>). <source>The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer</source>, <volume>43</volume>, <fpage>173</fpage>.</mixed-citation></ref></ref-list></back></article>